Renascience Cash Flow Statement

Financials in millions JPY. Fiscal year is April - March.

Millions JPY. Fiscal year is Apr - Mar.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '25 Sep 30, 2025	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022	Mar '21 Mar 31, 2021
Net Income	64	143	-256	-333	-253	-
Depreciation & Amortization	-	-	1	1	3	-
Loss (Gain) From Sale of Assets	1	1	4	-	11	-
Other Operating Activities	24	18	-1	-1	1	-
Change in Accounts Receivable	-	4	-4	-	-	-
Change in Accounts Payable	30	-10	26	67	-5	-
Change in Other Net Operating Assets	-396	-332	-	-18	13	-
Operating Cash Flow	-277	-176	-230	-284	-230	-
Capital Expenditures	-	-	-1	-2	-1	-
Investment in Securities	380	380	-	-	-	-
Other Investing Activities	-	2	-	2	1	-
Investing Cash Flow	380	382	-1	-	-	-
Long-Term Debt Issued	-	9	46	110	104	-
Long-Term Debt Repaid	-	-61	-	-	-380	-
Net Debt Issued (Repaid)	-61	-52	46	110	-276	-
Issuance of Common Stock	-	-	-	-	1,868	-
Other Financing Activities	-	-	-	-	-1	-
Financing Cash Flow	-61	-52	46	110	1,591	-
Miscellaneous Cash Flow Adjustments	-2	-1	-	-	-1	-
Net Cash Flow	40	153	-185	-174	1,360	-
Free Cash Flow	-277	-176	-231	-286	-231	-
Free Cash Flow Margin	-318.39%	-133.33%	-119.07%	-286.00%	-166.19%	-
Free Cash Flow Per Share	-21.79	-13.85	-18.17	-22.50	-20.28	-
Cash Interest Paid	-	-	-	-	4	-
Cash Income Tax Paid	31	2	1	1	-	-
Levered Free Cash Flow	-183.5	-98.88	-136.5	-159.75	-150	-
Unlevered Free Cash Flow	-183.5	-98.88	-136.5	-159.75	-146.88	-
Change in Working Capital	-366	-338	22	49	8	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.